Johnson & Johnson COVID-19 Vaccine is Good to Go Again
Last night, after two scientific meetings and a lengthy discussion of the risks and benefits, the U.S. Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC) recommended lifting the temporary “pause” on use of the Janssen (Johnson & Johnson) COVID-19 vaccine. After watching their public meetings and reviewing the data they discussed, I agree with lifting the pause and believe that the FDA’s and CDC’s actions illustrate how seriously they take vaccine safety.
As I’ve said before, physicians make decisions by balancing potential risks against potential benefits. Nothing is without risk; even choosing not to act has risks. In this instance, use of the vaccine was initially paused in order to examine risks of a rare blood clotting disorder among young women after receiving the Janssen (Johnson & Johnson) COVID-19 vaccine. However, the vaccine is highly effective in preventing COVID-19 infection, and the pause carried its own risk of less COVID-19 vaccine available in the U.S., fewer opportunities to vaccinate people against COVID-19 and ultimately, more cases of COVID-19 infection resulting from less vaccination. Read on for an explanation of why the benefits of vaccination (and risks of further pausing vaccination) outweigh the risks from the Janssen COVID-19 vaccine.
